Confusion over blood clot numbers with all four approved Covid-19 vaccines could cause more vaccine hesitancy.
Evaluate Vantage takes a look at the still-open deals that might come under threat from a new international clampdown.
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
Software-enabled medical devices pose unique challenges to regulators, and the US agency is getting serious about meeting them.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.